Evan Matlin joined MTS as a Partner in June 2024 where he focuses on the tools and diagnostics and life sciences sectors. With more than 18 years of experience, he has completed over 50 M&A transactions totaling more than $225bn of value for leading life sciences clients.

Prior to joining MTS, Mr. Matlin was a Managing Director at Barclays and Co-Head of Healthcare M&A. He also worked in London for three years, leading healthcare M&A efforts for the EMEA region. Before joining Barclays in 2016, Mr. Matlin was part of the healthcare teams at Deutsche Bank, Lazard, and CIBC World Markets.

Select representative clients for Mr. Matlin include Intercept, Ipsen, UCB, CVS Health, Danaher, Gilead, Pfizer, Merck, Nestle, Werfen, Medco, Royalty Pharma and Reckitt Benckiser.

Mr. Matlin graduated from The George Washington University in 2005 with a BA in Economics.